Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06248619 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
A Phase 3 study of Thyroid Eye Disease, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT06248619: Active Phase 3 study of Thyroid Eye Disease, sponsored by Amgen.
NCT06248619 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Amgen. The registered enrollment target is 89 participants, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 20 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06248619, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Teprotumumab
Study Locations (20)
Arizona
- Catalina Eye Care - NVISION - PPDS - Tucson
Illinois
- Advanced Quality Medical Research - Orland Park
Michigan
- W Kellogg Eye Center - Ann Arbor
Nevada
- Las Vegas Endocrinology - Henderson
New Jersey
- The Center for Eye and Facial Plastic Surgery - Somerset
Oregon
- Casey Eye Institute -515 SW Campus Dr - Portland
Pennsylvania
- Scheie Eye Institute - Philadelphia
Tennessee
- University of Tennessee Health Science Center - 848 Adams Ave - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2026-09-02 |
| Phase | Phase 3 |
What the registry record for NCT06248619 still lists
NCT06248619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 101-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06248619 names 20 study sites across 20 states, led by Arizona, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT06248619 about?
NCT06248619 is a clinical study titled "A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease". The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
What is the current status of trial NCT06248619?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2024-07-05. Estimated completion is 2026-09-02.
What conditions does trial NCT06248619 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06248619?
The interventions under investigation include: Placebo (OTHER), Teprotumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06248619?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06248619 being conducted?
This trial has 20 study locations across Arizona, Illinois, Michigan, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06248619's enrollment target sits among peer trials
89 10th of 15 higher than 6 of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI